Caricamento...
Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience
Antibody-mediated rejection (AMR) is not uncommon after renal transplantation and is harder to handle compared to cell-mediated rejection. When refractory to conventional therapies, rituximab is an attractive option. This study aims to examine the effectiveness of rituximab in refractory late acute...
Salvato in:
| Pubblicato in: | Indian J Nephrol |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Medknow Publications & Media Pvt Ltd
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5015507/ https://ncbi.nlm.nih.gov/pubmed/27795623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0971-4065.177207 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|